Search This Blog

Monday, June 24, 2013

Fountain Medical Development Looks to Improve Clinical Trial Efficiency with Oracle Health Sciences InForm GTM

Oracle Press Release

Fountain Medical Development Looks to Improve Clinical Trial Efficiency with Oracle Health Sciences InForm GTM

Clinical Development and Research Firm Joins Oracle CRO Advantage Program to Accelerate Expansion

Redwood Shores, Calif. – June 24, 2013

News Facts

Fountain Medical Development (FMD), a leading full-service contract research organization (CRO) operating across China, will use Oracle Health Sciences InForm GTM to deliver high-quality, cost-effective electronic data capture (EDC) clinical trial services to its growing client base.
FMD plans to use the solution to accelerate study design, ensure data quality and streamline data validation and analysis to help improve clinical trial efficiency and enable its clients to drive down costs.
Oracle Health Sciences InForm provides FMD with a single, scalable solution for effectively managing the full spectrum of study scenarios – from small population, rapid-turnaround studies to complex, multi-year trials spanning thousands of participants.
Oracle Health Sciences InForm’s multi-language capabilities support in-country as well as international studies, as FMD expands rapidly.
FMD also joined the Oracle CRO Advantage Program to support its growth strategy. The program provides a framework for driving CRO success with Oracle Health Sciences products through training, sales and marketing support and tools and regular communications on Oracle products and strategy. 

Supporting Quotes

“Oracle Health Sciences InForm is a critical component of our growth strategy. As a flexible and scalable solution, it will help us to improve clinical trial efficiency and accuracy on trials of all sizes, which increases the value we bring to our clients,” said Dan Zhang, chief executive officer, FMD. “Our ability to put the power of Oracle’s leading solution behind our studies is an important competitive advantage.”
“Focused on growth, FMD requires a comprehensive clinical data management solution that helps it to ensure data quality and drive new levels of clinical trial efficiency while supporting multiple types of studies,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences. “Oracle Health Sciences InForm will allow FMD to capture, manage and analyze study data with a single platform and use templates and automated edit check and validation capabilities to improve productivity and accelerate trial progress – an important value proposition for trial sponsors.”

Supporting Resources

About Oracle

Oracle engineers hardware and software to work together in the cloud and in your data center.  For more information about Oracle (NASDAQ:ORCL), visit www.oracle.com.

About Fountain Medical Development, Inc.

Fountain Medical Development Ltd. is a contract research organization (CRO) offering a full range of ICH GCP compliant clinical research services for multinational clients conducting clinical research in China and East Asia. For more service information about FMD, please visit www.fountain-med.com.

About Oracle in Industries

Oracle industry solutions leverage the company’s best-in-class portfolio of products to address complex business processes relevant to health sciences, helping speed time to market, reduce costs, and gain a competitive edge.

About Oracle Health Sciences

At Oracle, we believe that a more predictive, preventive, personalized and participatory system will help improve human health.  We can help accelerate this journey to personalized medicine through technology, data and insights. Oracle's solutions support industry initiatives to improve care quality and outcomes, reduce costs, and speed time to market for new treatments, therapies and devices. For more information, visit http://www.oracle.com/us/industries/health-sciences/index.html

Trademarks

Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.